)
Tandem Diabetes Care (TNDM) investor relations material
Tandem Diabetes Care Stifel 2025 Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Quarterly performance and business transformation
Q3 2025 results met expectations, with outperformance driven by improved pricing, especially in the pharmacy channel, and the launch of t:slim supplies ahead of schedule in September.
U.S. pump volumes were slightly down year-over-year, but sales rep productivity showed improvement, with momentum expected to continue into Q4, typically the largest quarter.
Pharmacy channel contributed 5% of U.S. revenue, with t:slim supplies and Mobi both playing significant roles; t:slim supplies are expected to drive further growth as penetration increases.
Pricing improvements in Q3 are expected to serve as a baseline for 2026, with mid-single-digit year-over-year price gains.
Guidance for Q4 and 2025 reflects consideration of seasonality, competitive dynamics, and the evolving business model, with confidence in meeting expectations.
Product pipeline and innovation
Tubeless Mobi is prioritized for commercialization over SteadiSet, with a 2026 launch targeted; further details expected in February.
New pump growth in 2026 is expected to be back-half weighted, with multiple drivers including Mobi tubeless, FreeStyle Libre 3 integration, Type-2 indication, and Mobi Android.
Fully closed loop pivotal trial is set to begin in 2026, leveraging a well-established algorithm and aiming for broad participant inclusion; FDA familiarity with the data is high.
SIGGI development is paced to avoid market confusion and to allow Mobi tubeless to establish itself, with future synergy expected between product lines.
Competitive landscape and market dynamics
The market remains large, expanding, and underpenetrated, with two main competitors and new entrants creating a dynamic environment.
Some market pausing is observed with new product launches, but the impact of recent entrants is still being assessed; more clarity is expected after Q4.
Competitive factors and the shift to pharmacy channel have been incorporated into guidance and business planning.
Next Tandem Diabetes Care earnings date
Next Tandem Diabetes Care earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)